|
|
|
|
FDA804-2
Multiple tumor and 6 types of normal organ tissue array (slide 2 of 2 slide set), replacing FDA803-2, recommended by FDA to test tissue specificity, 72 cases/72 cores, replaced by FDA807-2
|
|
| Microarray Panel: | Multiple tumor and normal tissue microarray, 54 cases of tumor of varieties of organ tissue and 6 types of normal organ (Uterus, Cervix, Striated muscle, Skin, Nerve, Mesothelium), each organ taken from 3 normal human individuals, together with FDA804-1 to make FDA804 set, single core per case |
| Cores: | 72 |
|
| Cases: | 72 |
| Layout: | 9 cols × 8 rows |
| Core Diameter: | 1.5 mm |
| Thickness: | 5 µm | | Quality Control: | Anti-Actin confirmed | | Applications: | Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page. |
| Notes: | Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure. |
*Tissue Microarray Slide Types:
- Unstained: unstained
paraffin
tissue microarray slide.
- Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
- H & E: Hematoxylin and Eosin stained tissue microarray slide.
Microarray Panel Display  | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | |
| A |
|
|
|
|
|
|
|
|
|
|
| B |
|
|
|
|
|
|
|
|
|
|
| C |
|
|
|
|
|
|
|
|
|
|
| D |
|
|
|
|
|
|
|
|
|
|
| E |
|
|
|
|
|
|
|
|
|
|
| F |
|
|
|
|
|
|
|
|
|
|
| G |
|
|
|
|
|
|
|
|
|
|
| H |
|
|
|
|
|
|
|
|
|
 |
|
| Legend: | Bla - Bladder,
Bon - Bone,
Bra - Brain,
Bre - Breast,
Col - Colon,
Eso - Esophagus,
Kid - Kidney,
Liv - Liver,
Lun - Lung,
Lym - Lymph node,
Med - Mediastinum,
Mes - Mesothelium,
Ner - Nerve,
Ova - Ovary,
Pan - Pancreas,
Per - Peritoneum,
Pro - Prostate,
Rec - Rectum,
Ret - Retroperitoneum,
Ski - Skin,
Sma - Small intestine,
Smo - Smooth muscle,
Spl - Spleen,
Sto - Stomach,
Str - Striated muscle,
Tes - Testis,
Thr - Thyroid,
Ute - Uterine cervix
- Benign tumor,
- Malignant tumor,
- Normal tissue
|
Specification Sheet
| Pos |
No. |
Sex |
Age |
Organ |
Pathology diagnosis |
Grade |
Type † |
|
A1 |
1 |
F |
21 |
Uterus |
Normal endometrial tissue |
– |
Normal |
|
A2 |
2 |
F |
21 |
Uterus |
Normal endometrial tissue |
– |
Normal |
|
A3 |
3 |
F |
58 |
Uterus |
Normal endometrial tissue |
– |
Normal |
|
A4 |
4 |
F |
15 |
Uterine cervix |
Normal cervix tissue |
– |
Normal |
|
A5 |
5 |
F |
21 |
Uterine cervix |
Normal cervix tissue |
– |
Normal |
|
A6 |
6 |
F |
35 |
Uterine cervix |
Normal cervix tissue |
– |
Normal |
|
A7 |
7 |
M |
40 |
Striated muscle |
Normal skeletal muscle tissue |
– |
Normal |
|
A8 |
8 |
M |
30 |
Striated muscle |
Normal skeletal muscle tissue (sparse) |
– |
Normal |
|
A9 |
9 |
M |
40 |
Striated muscle |
Normal skeletal muscle tissue (sparse) |
– |
Normal |
|
B1 |
10 |
M |
35 |
Skin |
Normal dermatic tissue |
– |
Normal |
|
B2 |
11 |
M |
40 |
Skin |
Normal dermatic tissue |
– |
Normal |
|
B3 |
12 |
M |
40 |
Skin |
Normal dermatic tissue |
– |
Normal |
|
B4 |
13 |
F |
15 |
Nerve |
Normal nerve tissue (sparse) |
– |
Normal |
|
B5 |
14 |
M |
22 |
Nerve |
Normal nerve tissue |
– |
Normal |
|
B6 |
15 |
F |
62 |
Nerve |
Normal nerve tissue (fibrous tissue and blood vessel) |
– |
Normal |
|
B7 |
16 |
M |
48 |
Mesothelium |
Normal mesothelium and lung tissue (sparse) |
– |
Normal |
|
B8 |
17 |
M |
22 |
Mesothelium |
Normal mesothelium and lung tissue (sparse) |
– |
Normal |
|
B9 |
18 |
M |
40 |
Mesothelium |
Normal mesothelium tissue (lung tissue) |
– |
Normal |
|
C1 |
19 |
M |
39 |
Brain |
Glioblastoma |
– |
Malignant |
|
C2 |
20 |
M |
43 |
Brain |
Atypical meningioma |
– |
Malignant |
|
C3 |
21 |
F |
15 |
Brain |
Malignant ependymoma |
– |
Malignant |
|
C4 |
22 |
F |
61 |
Brain |
Malignant oligodendroglioma |
– |
Malignant |
|
C5 |
23 |
F |
53 |
Ovary |
Serous papillary adenocarcinoma |
3 |
Malignant |
|
C6 |
24 |
F |
29 |
Ovary |
Mucinous papillary adenocarcinoma |
2–3 |
Malignant |
|
C7 |
25 |
F |
12 |
Pancreas |
Islet cell carcinoma |
– |
Malignant |
|
C8 |
26 |
M |
64 |
Pancreas |
Adenocarcinoma |
3 |
Malignant |
|
C9 |
27 |
M |
32 |
Testis |
Seminoma (sparse) |
– |
Malignant |
|
D1 |
28 |
M |
30 |
Testis |
Embryonal carcinoma |
– |
Malignant |
|
D2 |
29 |
F |
33 |
Thyroid |
Medullary carcinoma |
– |
Malignant |
|
D3 |
30 |
M |
36 |
Thyroid |
Papillary carcinoma |
– |
Malignant |
|
D4 |
31 |
F |
50 |
Breast |
Intraductal carcinoma |
– |
Malignant |
|
D5 |
32 |
F |
49 |
Breast |
Lobular carcinoma in situ (breast tissue) |
– |
Malignant |
|
D6 |
33 |
F |
39 |
Breast |
Invasive ductal carcinoma |
2 |
Malignant |
|
D7 |
34 |
M |
21 |
Spleen |
Diffuse B-cell lymphoma |
– |
Malignant |
|
D8 |
35 |
F |
45 |
Lung |
Small cell undifferentiated carcinoma |
4 |
Malignant |
|
D9 |
36 |
M |
74 |
Lung |
Squamous cell carcinoma (sparse) with necrosis |
3 |
Malignant |
|
E1 |
37 |
F |
59 |
Lung |
Adenocarcinoma |
3 |
Malignant |
|
E2 |
38 |
M |
50 |
Esophagus |
Squamous cell carcinoma |
2 |
Malignant |
|
E3 |
39 |
F |
67 |
Esophagus |
Adenocarcinoma |
3 |
Malignant |
|
E4 |
40 |
F |
73 |
Stomach |
Mucinous adenocarcinoma |
3 |
Malignant |
|
E5 |
41 |
F |
51 |
Small intestine |
Adenocarcinoma |
2 |
Malignant |
|
E6 |
42 |
F |
71 |
Small intestine |
Intermediate grade interstitialoma |
– |
Malignant |
|
E7 |
43 |
M |
70 |
Colon |
Adenocarcinoma |
3 |
Malignant |
|
E8 |
44 |
M |
54 |
Colon |
Intermediate grade interstitialoma |
– |
Malignant |
|
E9 |
45 |
M |
68 |
Rectum |
Adenocarcinoma |
3 |
Malignant |
|
F1 |
46 |
M |
32 |
Rectum |
Intermediate grade interstitialoma |
– |
Malignant |
|
F2 |
47 |
M |
61 |
Liver |
Hepatocellular carcinoma |
2 |
Malignant |
|
F3 |
48 |
F |
17 |
Liver |
Hepatoblastoma |
– |
Malignant |
|
F4 |
49 |
M |
55 |
Kidney |
Clear cell carcinoma |
– |
Malignant |
|
F5 |
50 |
M |
67 |
Prostate |
Adenocarcinoma (prostate tissue sparse) |
– |
Malignant |
|
F6 |
51 |
M |
66 |
Prostate |
Transitional cell carcinoma |
3 |
Malignant |
|
F7 |
52 |
F |
45 |
Uterus |
Leiomyoma |
– |
Malignant |
|
F8 |
53 |
F |
48 |
Uterus |
Endometrial adenocarcinoma |
3 |
Malignant |
|
F9 |
54 |
F |
39 |
Uterus |
Clear cell carcinoma of endometrium |
– |
Malignant |
|
G1 |
55 |
F |
36 |
Uterine cervix |
Squamous cell carcinoma |
3 |
Malignant |
|
G2 |
56 |
F |
39 |
Uterine cervix |
Squamous cell carcinoma |
3 |
Malignant |
|
G3 |
57 |
F |
20 |
Striated muscle |
Embryonal rhabdomyosarcom of left leg |
– |
Malignant |
|
G4 |
58 |
F |
70 |
Rectum |
Malignant melanoma of anus |
– |
Malignant |
|
G5 |
59 |
F |
65 |
Skin |
Basal cell carcinoma of head |
– |
Malignant |
|
G6 |
60 |
M |
46 |
Skin |
Squamous cell carcinoma of left chest wall |
2 |
Malignant |
|
G7 |
61 |
M |
59 |
Mediastinum |
Neurofibroma |
– |
Benign |
|
G8 |
62 |
F |
3 |
Retroperitoneum |
Neuroblastoma of retroperitoneum |
– |
Malignant |
|
G9 |
63 |
M |
60 |
Peritoneum |
Epithelial malignant mesothelioma |
– |
Malignant |
|
H1 |
64 |
M |
42 |
Lymph node |
Diffuse malignant lymphoma |
– |
Malignant |
|
H2 |
65 |
M |
53 |
Lymph node |
Diffuse malignant lymphoma |
– |
Malignant |
|
H3 |
66 |
M |
53 |
Lymph node |
Hodgkin's lymphoma of supraclavicular |
– |
Malignant |
|
H4 |
67 |
F |
68 |
Lymph node |
Diffuse malignant lymphoma of mandible |
– |
Malignant |
|
H5 |
68 |
F |
72 |
Bladder |
Transitional cell carcinoma with squamous metaplasia |
3 |
Malignant |
|
H6 |
69 |
M |
62 |
Bladder |
Low grade leiomyosarcoma |
– |
Malignant |
|
H7 |
70 |
F |
7 |
Bone |
Osteosarcoma of right femur inferior extremity |
– |
Malignant |
|
H8 |
71 |
F |
48 |
Retroperitoneum |
Spindle cell rhabdomyosarcoma of retroperitoneum |
– |
Malignant |
|
H9 |
72 |
F |
60 |
Smooth muscle |
Intermediate grade leiomyosarcoma of left buttock |
– |
Malignant |
|
–
|
– |
M |
58 |
Skin |
Malignant melanoma (tissue marker) |
– |
Malignant |
"-" No grading available. *Tissue dots may be missing or histologically unidentifiable
† For precise diagnosis, refer to pathology description.
**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.
|
|